BalanceSense, LLC Awards StudyManager Phase II Study for Returning Troops with Mild-Trauma Brain Injury
StudyManager
announced that
BalanceSense, LLC
awarded StudyManager an eight-site, Phase II Army contract to implement Evolve CTMS and EDC.
BalanceSense sought a flexible, easy to use solution for the management of clinical data captured by physical therapists treating returning troops with mild-trauma brain injuries, and to centralize, track, and manage study progress.
“We are pleased to have the opportunity to contribute to this important effort in working with Dr. Karen Atkins, PhD, PT, Balance Sense, LLC and her team,” said Sue Blecman, Vice President of Sales, StudyManager. “It’s a privilege for StudyManager and Evolve to have been selected as one of BalanceSense’s civilian partners to support much needed treatment for our returning troops. We look forward to their clinical and operational success with this study.”
Evolve's web-based interface integrates clinical trial management and electronic data capture tools. These features are very scalable, and can be used together seamlessly or independently. Evolve enables users to create a single, centralized and secure location for key study information, simplifying study operations and enhancing team efficiency.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
